Corcept Therapeutics sees 124% jump in Q4 revenue; shares ahead 13% premarket [Seeking Alpha]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Seeking Alpha
Corcept Therapeutics sees 124% jump in Q4 revenue; shares ahead 13% premarketOn apreliminary basis, Corcept Pharmaceuticals (NASDAQ:CORT) expects Q4 revenue of $53.3M, up 124% from a year ago ($23.8M). 2017 revenue should be $159.2M (+96%).Quick assets totaled $104M at the end of December.2018 Guidance: Revenue: $275M - 300M.CEO Joseph Belanoff, M.D., says, “Our Cushing’s syndrome franchise had an outstanding year. More and more physicians realize that hypercortisolism frequently goes undiagnosed and as a consequence are screening more patients for the disease. There is also a growing realization that for many patients cortisol modulation with Korlym® is the best medical treatment. Our 2017 growth reflected the simple fact that more physicians are prescribing Korlym for more patients – a shift in medical practice we expect to continue in 2018 and beyond.”Shares are up13% premarket.See all stocks on the move »Now read:Your Daily Pharma Scoop: Achaogen Update, Seattle Genetics Acquires
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study [Yahoo! Finance]Yahoo! Finance
- Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.MarketBeat
- Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing's Syndrome [Yahoo! Finance]Yahoo! Finance
- Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s SyndromeGlobeNewswire
- Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action SettlementAccesswire
CORT
Earnings
- 2/15/24 - Beat
CORT
Analyst Actions
- 4/23/24 - HC Wainwright
CORT
Sec Filings
- 4/18/24 - Form DEFA14A
- 4/17/24 - Form ARS
- 4/17/24 - Form 8-K
- CORT's page on the SEC website